The Street’s Key Stock Analysts Research Reports

$AGN, $BDSI, $CREE, $DLTR, $LLY, $ENDP, $BTU

Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of The Street’s Key analysts outlook for Key issues for Thursday as follows:

Allergan PLC (NYSE:AGN) was started with a Buy rating and assigned a $178 target price at SunTrust Robinson Humphrey. The 52-wk trading range is 125.84 – 197.00, and the consensus analyst target is 184.29.

BioDelivery Sciences International Inc. (NASDAQ:BDSI) was started with a Buy rating and assigned a 7 target price at SunTrust Robinson Humphrey.

Cree Inc. (NASDAQ:CREE) was raised to Market Outperform from Market Perform with a $74 price target at JMP Securities. It has a $56.29 consensus target price.

Dollar Tree Inc. (NASDAQ:DLTR): analysts raised DLTR to Outperform from Market Perform and the target price was raised to 117 from 103 at Telsey Advisory Group.

Eli Lilly and Co. (NYSE:LLY): analysts started LLY with a Buy rating and assigned a $140 price target at UBS. The 52-week range is $74.51 to $130.75, and the consensus analyst target is $122.00.

Endo International PLC (NASDAQ:ENDP) was started with a Buy rating and assigned a 13 target price at SunTrust Robinson Humphrey.

Peabody Energy Inc. (NYSE:BTU) was started as Market Perform and assigned a 34 price target at BMO Capital Markets. The 52-wk trading range is 28.07 – 47.84, and the consensus analyst target is 40.67.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

You must be logged in to post comments :  
CONNECT WITH